New antibody drug HB0056 begins first human safety trial
NCT ID NCT06612970
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial is testing the safety of a single dose of HB0056, a new bispecific antibody, in 46 healthy adults aged 18 to 55. Participants are randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The study does not aim to treat any disease but to gather essential safety data before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HB0056 (a bispecific antibody targeting TSLP and IL-11)
What this could lead to
If safe, this could pave the way for future studies of HB0056 in diseases involving inflammation or immune responses.
What could go wrong
This is an early Phase 1 trial in healthy people, so it won't show if the drug works for any disease. Side effects are possible and unknown yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Clinical Research
RECRUITINGChristchurch, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••